ArticleJournal of clinical and translational research2020
New TNM staging in lung cancer (8
Article in Journal of clinical and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer.Oncology letters · 2025Article
- Effects of suturing of the mediastinal pleura on lessening pleural effusions after lobectomy in patients with non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye.Medical science monitor : international medical journal of experimental and clinical research · 2025Observational
- Comparison of five scores to predict mortality in malignant pleural effusion.Updates in surgery · 2024Article
- Two-Year Experience of a Center of Excellence for the Comprehensive Management of Non-Small Cell Lung Cancer at a Fourth-Level Hospital in Bogota, Colombia: Observational Case Series Study and Retrospective Analysis.Journal of clinical medicine · 2024Article
- Bronchial carcinoid: a neuroendocrine manifestation-presented as bronchospasm and hypertension during resection.Indian journal of thoracic and cardiovascular surgery · 2024Article
- Prognostic Value of Lymph Node Ratio (LNR) in Patients with Postoperative N2 Feature in Non-Small Cell Lung Cancer (NSCLC).Journal of clinical medicine · 2024Article
- New developments in the imaging of lung cancer.Breathe (Sheffield, England) · 2024Review
- Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Radial Endobronchial Ultrasound for Lung Cancer Diagnosis: Tips and Tricks.Journal of Cancer · 2022Article
- Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments.Plants (Basel, Switzerland) · 2021Review
- The association of metabolic positron emission tomography/computed tomography parameters with survival in small cell lung cancer.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarrying out a correct anatomical classification of lung cancer is crucial to take clinical and therapeutic decisions in each patient.
aimTNM staging classification provides an accurate anatomical description about the extension of the disease; however, the anatomical burden of the disease is just one aspect that changes the prognosis. RELEVANCE FOR PATIENTS: TNM staging classification is a tool that predicts survival, but we must consider that TNM is just one of the factors that concern the prognosis. The impact of a factor over the prognosis is complex due to: It depends on the specific environment, the treatment strategy, among others, and our level of certainty makes difficult to include all the factors just in a group of stages. In some groups, there are difficulties to get large series due to the low frequency of cases and the small number of events (metastasis, locoregional recurrence). It does not allow to obtain evidence in a short period of time. On the other hand, in the next years, new markers will be incorporated in the coming years, which are going to be included in the new TNM classification. It could help to improve the classification giving more information about prognosis and risk of recurrence. All these aspects are being used by the International Association for the Study of Lung Cancer (IASLC) to develop a new prognosis model. This continues the evolution of TNM system, allows us to overcome the difficulties, and build a flexible framework enough to continue improving the individual prognosis of the patients.
Indexed as
Identifiers
33521375PMC7837738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.